You are now leaving GSK Malta Health Portal

You are about to leave a GSK Website. By clicking this link, you will be taken to an external website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on this site. If you do not wish to leave this website, click on “Go Back” below:

Continue

Go back

MLT_GIB/OTH/0007/17m
Date of preparation: March 2018

Licensed indication

Synflorix is indicated for active immunisation against invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumonia in infants and children from 6 weeks up to 5 years of age. 1

See the full SPC for further information before prescribing. 

Reference:

  1. Synflorix Summary of Product Characteristics,GlaxoSmithKline.

 

Synflorix is a trade mark of the GlaxoSmithKline group of companies.